Vizilite^® Plus oral lesion identification and marking system

The newest tool in the fight against oral disease is the Vizilite^® Plus oral lesion identification and marking system.

Vizilite^® Plus, from Zila Pharmaceuticals, combines the oral screening technology of Vizilite^®, an advanced chemiluminescent light technology to help detect oral abnormalities, with TBlue630T. TBlue630 is the only patented pharmaceutical-grade form of toluidine blue that has been cleared by the FDA for use in marking lesions identified during a Vizilite^® examination.

Vizilite^® Plus makes oral screening more comprehensive than ever before and is indicated for use in individuals at increased risk of oral cancer. If Vizilite^® reveals an abnormality, TBlue630 can be used to mark suspicious lesions for further evaluation.